[exclusive] after 17 anticancer drugs are included in the medical insurance catalogue, the winning regions will soar?

On October 10, the State Medical Security Bureau issued the notice on including 17 kinds of drugs into the category B scope of the national basic medical insurance, work injury insurance and maternity insurance drugs catalogue After more than three months of negotiation, 17 kinds of anticancer drugs were included in the medical insurance reimbursement catalogue Compared with the average retail price of 17 negotiated drugs, the average drop was 56.7%, which was 44% lower than that of 36 drugs included in the medical insurance catalogue last year Will the bid price of 17 anticancer drugs continue to decrease? Can such a large price cut bring good news of winning the bid in different places? We can take a look at the situation of winning the bid of drugs after they were included in the medical insurance catalogue last year On July 13, 2017, the Ministry of human resources and social security issued the notice on including 36 kinds of drugs into the category B scope of the national basic medical insurance, work injury insurance and maternity insurance drug catalog, which included 36 kinds of drugs into the medical insurance catalog, including 16 Western anti-cancer drugs According to the statistics of the bid winning information query database of smart drugs, the average bid winning prices of 16 varieties with different specifications in various regions in 2018 are as follows: It can be seen from the table that, compared with the negotiation price of medical insurance, the average bid winning price of 16 anticancer drugs in 2018 has been reduced by 11, but the decrease is not very large The relatively large decrease is bortezomib for injection, with the drop of 1mg / bottle reaching 19.92% Therefore, we can also speculate that the bidding price of 17 anticancer drugs entering the medical insurance catalog in different places may be lower than the current price, but the decrease is not big 10 new varieties on the market or more than 10 winning regions? At the same time, the author also sorted out the changes in the number of winning regions in 2016-2018 of 16 Western anticancer drugs included in the medical insurance catalog last year The details are as follows: from the table, we can see that in 2016, 14 of the 16 anti-cancer varieties won the bid in 0-5 regions By 2017, except xidaban tablets and recombinant human interferon β - 1B injection, other varieties won the bid in 10 or more regions Compared with this year, 10 of the 17 anti-cancer drugs included in the medical insurance catalog are new varieties approved for marketing only in 2017-2018 According to statistics, there are 5 varieties that have not won the bid, and only 3 of the most winning regions are afatinib maleate (see the figure below for details of 10 drug winning regions) According to last year's growth momentum, today's bid winning areas for these new varieties will soar to 10 or more Among the 16 anticancer drugs included in the medical insurance catalogue in 2017, in addition to the rapidly increasing varieties from 2016 to 2017, the bid winning areas of six varieties, such as erlotinib hydrochloride, lapatinib toluene sulfonate, apatinib mesylate, abiolone acetate, Everest and lenalidomide capsules, have achieved continuous growth in 2016-2018 Then, 17 anticancer drugs included in the medical insurance catalogue in 2018 Which regions will achieve continuous growth? We'll see Statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.